A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East (Q37970382)

26 August 2017

title

A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East (English)

1 reference

26 August 2017

0 references

1 reference

1 reference

Specialist Panel on Chronic Hepatitis B in the Middle East

series ordinal

1 reference

26 August 2017

language of work or name

1 reference

13 September 2011

1 reference

Journal of Viral Hepatitis

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

9-22

1 reference

Molecular virology of hepatitis B virus for clinicians

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis C antibody prevalence in blood donors in different governorates in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Epidemiologic evaluation of the immunity against hepatitis B in Alexandria, Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Prevalence of viral markers among first-time Arab blood donors in Kuwait.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Prevalence of antibodies against hepatitis B virus and hepatitis C virus among blood donors in Lebanon, 1997-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Sero-epidemiology of hepatitis B infection in pregnant women in Oman, Qatar and the United Arab Emirates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Anti-hepatits B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Serology based disease status of Pakistani population infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Temporal trends in hepatitis B and C infection in family blood donors from interior Sindh, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Prevalence of seromarkers of HBV and HCV among blood donors in eastern Saudi Arabia, 1998-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Prevalence of hepatitis B virus markers among blood donors in a tertiary hospital in Tabuk, northwestern Saudi Arabia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Prevalence of blood-borne viral hepatitis in different communities in Yemen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Trend in incidence of hepatitis B virus infection during a decade of universal childhood hepatitis B vaccination in Saudi Arabia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Prevalence of hepatitis B among Afghan refugees living in Balochistan, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Changing patterns of acute viral hepatitis at a major urban referral center in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis B virus genotypes in southwest Iran: molecular, serological and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis B genotypes: relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Management of patients with HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Molecular epidemiology of Hepatitis B virus genotypes in Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Risk factors for hepatocellular carcinoma in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatocellular carcinoma in Saudi Arabia: role of hepatitis B and C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Long-term outcomes in hepatitis B: the REVEAL-HBV study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Horizontal transmission of hepatitis B virus in children with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Intra-familial spread of hepatitis B virus infection in eastern Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Pakistan:a cirrhotic state?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Population beliefs about the efficacy of injections in Pakistan's Sindh province

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis B epidemiology in Asia, the Middle East and Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Vaccination coverage in the South-East Anatolian Project (SEAP) region and factors influencing low coverage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Hepatitis B virus among schoolchildren in an endemic area in Egypt over a decade: impact of hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Evaluation of immune response to Hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01511.X

10.1111/J.1365-2893.2011.01511.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference